Imagine you are a business owner and you are presented with an enormous gap in your market that needs filling and there is a dearth of competition.
But what if the products that would fill that gap are not only unprofitable, but become less valuable the more people use them? What would you do? This is the issue facing the pharmaceutical industry, which the world depends on to provide the bedrock of modern healthcare - antibiotics. Investment in new antibiotics has slowed to the lowest rate in history, and big pharmaceutical companies have largely abandoned the field. Modern healthcare systems are built on the ability to control infection, and our tools in that fight - antibiotics - were in crisis even before Covid-19 hit. C...
To continue reading this article...
Join Investment Week for free
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes